Connect with us

Accounting

Trump plans new tariff push with 100% rate on patented drugs

Published

on

President Donald Trump announced a fresh round of tariffs on pharmaceuticals, heavy trucks and furniture, including a 100% duty on patented drugs unless the producer is building a manufacturing plant in the U.S.

“Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump posted on social media Thursday, without offering specifics on which producers will be impacted. “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”

Trump’s post was one of several on new industry-focused tariffs set to begin next Wednesday. Imported heavy trucks will be subject to a 25% duty, kitchen cabinets and bathroom vanities will be hit with a 50% charge, and upholstered furniture imports are to be taxed at 30%. 

Taken together, the moves amount to a rapid expansion of Trump’s tariff regime, which he started to erect shortly after taking office. It comes at a time when the president has flexed his executive powers like none of his modern predecessors. Just as Trump made the levies public, former FBI Director James Comey — a longtime Trump political enemy — was indicted on perjury charges under heavy pressure from the president. 

Most European drugmakers slumped in early trading, led by a drop of as much as 3.1% in Novo Nordisk A/S. GSK Plc slid as much as 1.1%, while AstraZeneca Plc fell as much as 1.6%.

“Trump is never going to be done with tariffs,” Deborah Elms, head of trade policy at Hinrich Foundation, said on Bloomberg Television.

Trump’s posts offered no further details. The pharmaceuticals plan, as described by the president, may allow for wide exemptions for companies with presences in the U.S. The White House did not immediately respond to a request for more specifics.

The levy on branded pharmaceuticals may raise the average U.S. tariff rate by up to 3.3 percentage points, according to Bloomberg Economics, though the impact may be offset by the exemption for companies building local manufacturing facilities. Singapore and Switzerland are the countries most exposed to the move.

Major drugmakers, including Merck & Co., AstraZeneca and Johnson & Johnson, have announced billions of dollars in planned U.S. manufacturing investments in the months since Trump’s inauguration, following the president’s repeated threats to impose levies on drugs imported from overseas.

“The actual comment from the President is direct but its impact may be somewhere between nebulous and negligible,” Mizuho Securities health-care specialist Jared Holz said in a note. “All major players have some production presence domestically and almost all have announced increased investment directly tied towards local manufacturing.”

Still, some could be left vulnerable. Multinational drugmakers have said they primarily rely on plants in the U.S. to supply the domestic market, but not all of them have broken ground on their promised expansions.

“The countries most exposed to the move are Singapore and Switzerland,” wrote Nicole Gorton-Caratelli and Maeva Cousin of Bloomberg Economics. “The U.K. also has some important pharmaceuticals exports to the U.S, — its trade agreement with the U.S. mentioned that special rates would be considered in the event of new Section 232 tariff, but no formal rate was agreed. A similar approach seems also to be in place for Japan.” 

Several of America’s best-selling drugs are still largely produced abroad. The main ingredient in Novo Nordisk’s diabetes and weight-loss juggernauts Ozempic and Wegovy is made in Denmark, while a critical first step in the production of Mounjaro, Eli Lilly & Co.’s rival GLP-1, happens in Ireland.

Johnson & Johnson’s immune-disease therapy Stelara and cancer drug Darzalex are manufactured in Switzerland and Denmark, respectively. Opdivo, Bristol-Myers Squibb Co.’s blockbuster cancer immunotherapy, relies heavily on production in Ireland and Switzerland. Novartis AG’s Cosentyx and Entresto also originate in Swiss facilities. 

Unless those companies can show they’ve broken ground on U.S. sites that will take on production, their biggest sellers could face tariffs that would instantly double import costs. Novo Nordisk, for example, is building a new 1.4 million square foot manufacturing plant in North Carolina, while Eli Lilly earlier this year announced plans for four new U.S. manufacturing sites. 

Some Japanese pharmaceutical companies also make drugs for rare and serious conditions that might be subject to the new tariff. Hemlibra, used to help clot blood in hemophilia patients, is made by Japanese drugmaker Chugai Pharmaceutical Co, while Enhertu, used to deliver chemotherapy directly to breast cancer cells without damaging healthy ones, is made by Daiichi Sankyo Co.

Trump is imposing product-based levies using Section 232 of the Trade Expansion Act, which allows the administration to impose tariffs without congressional action if imports are deemed a national security threat. The approach has already been used to impose levies on automobile, copper, steel and aluminum imports.

Other duties on critical imports, including semiconductors and critical minerals, are expected in the coming weeks. His government has also launched investigations into imports of robotics, industrial machinery and medical devices that could have wide-ranging effects for domestic manufacturers. 

The Trump administration is also weighing a plan to reduce U.S. reliance on overseas semiconductor manufacturing, the Wall Street Journal reported Friday, citing people familiar with the matter. It will aim to have companies make the same number of chips in the U.S. as they do overseas, the people said, adding that Commerce Secretary Howard Lutnick had spoken to some corporate executives about the matter.

In April, the Commerce Department began investigating the impact of all drug imports — both finished generic and branded medicines as well as the ingredients used to make them — on U.S. national security.

Trump has previewed his move on pharmaceutical tariffs for months, albeit in haphazard fashion. In early July, Trump said he intended to give drug companies some leeway to bring their operations to the U.S. before slapping tariffs of as much as 200% on their products. Then, on July 15, the president said he was likely to begin imposing tariffs on pharmaceuticals by the end of the month. 

If the new tariffs don’t stack on top of existing country deals, their impact will be limited as several major foreign production economies have reached trade deals with the White House. For example, in late July, the US and EU reached a broad trade agreement that includes 15% tariffs on pharmaceutical products.

The industry-based tariffs offer potentially more durability than the country-level levies Trump imposed under the International Emergency Economic Powers Act. The Supreme Court has agreed to consider a challenge to those tariffs, after two lower courts have already declared them illegal.

Trump has also targeted the drug industry in other ways. The tariff announcement follows an executive order that attempts to reduce prices by aligning American drug costs with the lowest prices paid abroad. The order, which Trump signed May 12, asks companies to cut prices voluntarily or face regulatory measures, though it’s unclear how exactly that will be enacted.

The president announced his tariff plan days ahead of a White House-imposed deadline for 17 of the biggest drug manufacturers to voluntarily reduce what they charge the U.S. government for approved medicines and set the price of new drugs on par with what they cost overseas. In a July letter to company CEOs, Trump threatened to “deploy every tool in our arsenal” to punish companies that don’t comply by Monday.

“This refreshed threat on pharma has been brought up by Trump several times as a negotiation tool,” said Anna Wu, cross-asset strategist at VanEck Associates Corp. in Sydney.

Continue Reading

Accounting

SEC’s Semiannual Reporting Proposal Faces Investor Pushback: What CFOs Need to Know

Published

on

U.S. Securities and Exchange Commission (SEC)

A proposal from the U.S. Securities and Exchange Commission to potentially shift some public companies away from quarterly financial reporting toward a semiannual model is drawing significant pushback from investors, even as it continues moving through the regulatory process. The debate has direct implications for corporate finance teams, auditors, and the broader transparency of U.S. capital markets.

What the SEC Proposed

According to a summary published by accounting advisory firm Cohen & Co., the SEC issued a proposed rule on May 19, 2026, aimed at simplifying financial reporting requirements for many U.S. public companies. The proposal would potentially reduce the frequency of certain mandatory disclosures from quarterly to semiannual, a structural change that has not been made to core U.S. reporting requirements in decades.

The proposal follows an extended debate within U.S. policy circles, with proponents arguing that reduced reporting frequency could lower compliance costs and free up management time for longer-term strategic planning rather than quarter-to-quarter results management.

Why Investors Are Pushing Back

Comment letters submitted in response to the proposal have been extensive, and according to Cohen & Co.’s review of the public record, investors “appear to be largely opposed” to the shift, viewing frequent interim reporting as a core benefit of U.S. capital markets relative to other jurisdictions.

Accounting and law firms have taken a more measured position, generally urging any changes to remain aligned with the Financial Accounting Standards Board (FASB), whose existing disclosure requirements and guidance are built around a quarterly reporting cadence. A shift to semiannual reporting without corresponding changes to FASB guidance could create friction between SEC filing requirements and GAAP-based disclosure expectations.

Lessons From the U.K. Experience

The debate is not without precedent. The United Kingdom moved away from mandatory quarterly reporting for listed companies in 2014, returning to a semiannual disclosure requirement. According to Cohen & Co.’s analysis, that experience offers a cautionary data point: there was no measurable increase in capital expenditure or R&D investment following the change, while analyst coverage of affected companies declined as reliable interim information became less available — a particular risk for smaller and newly public companies that rely on analyst coverage to maintain investor visibility.

Practical Implications for Finance Teams

Beyond the debate over disclosure philosophy, the proposal carries practical complications. Many companies have debt covenants and credit agreements structured around quarterly financial delivery; a shift to semiannual reporting could require renegotiating those terms. Reduced reporting frequency would also extend the “window of market silence” between disclosures, a factor that governance and investor-relations teams would need to manage carefully to avoid information asymmetry.

Separately, and unrelated to the reporting-frequency debate, the SEC and FASB have continued finalizing more routine updates this year. New Accounting Standards Updates are taking effect for December 31, 2026, fiscal year-ends covering income tax disclosures, credit loss measurement, induced debt conversions, and stock compensation, according to Eide Bailly’s review of 2026 ASU activity. Additional guidance on paid-in-kind dividends and environmental credits is also on the near-term horizon.

What to Watch Next

The semiannual reporting proposal remains in the comment and review phase, and no final rule has been adopted as of this writing. Finance leaders should monitor the SEC’s regulatory agenda for further movement, while treating the current quarterly reporting requirement as the operative standard until any final rule is issued and an effective date is set.

Given the extent of investor opposition documented in the comment file, a full shift to mandatory semiannual reporting appears more likely to result in either a scaled-back compromise or continued study rather than swift adoption — though the SEC’s ultimate direction remains uncertain.

 

Continue Reading

Accounting

AI-Driven Automation and Continuous Accounting Frameworks

Published

on

The accounting profession is undergoing a fundamental structural transition as enterprise finance departments shift from periodic month-end closes toward automated continuous accounting models. By integrating specialized machine learning algorithms directly into enterprise resource planning (ERP) platforms, chief accounting officers are transforming financial reporting from a retrospective exercise into a real-time operational asset.

The Shift from Periodic Close to Continuous Financial Reporting
Traditional accounting workflows heavily relied on manual data reconciliation, spreadsheet calculations, and multi-week closing cycles at the end of each fiscal period. In contrast, continuous accounting frameworks utilize automated software agents to process, validate, and post transactional data in real time as business activities occur.

Automated bank reconciliation tools cross-reference incoming bank feeds, invoice records, and purchase orders automatically. By resolving transactional variances instantly throughout the month, corporate accounting teams eliminate the traditional workload spikes associated with quarterly and annual closes.

Machine Learning in Audit Trails and Anomaly Detection
Advanced natural language processing (NLP) and machine learning tools are redefining internal audit and financial control environments. Automated systems analyze 100% of general ledger entries, identifying anomalous transactions, duplicate payments, and unauthorized journal entries in real time.

Rather than relying on random statistical sampling, corporate internal auditors can focus their attention on high-risk flags automatically surfaced by algorithmic monitoring platforms. This continuous risk assessment strengthens internal controls over financial reporting (ICFR) and significantly reduces fraud risk.

Evolving Roles for Accounting Professionals
As routine data entry and manual reconciliation tasks become fully automated, the skill set required for accounting professionals is shifting toward data analysis, system design, and strategic business advisory.
– Systems Governance: Accountants are increasingly responsible for monitoring algorithmic accuracy and managing data integration pipelines.
– Business Partnership: Finance professionals leverage real-time financial dashboards to advise operational leaders on margin management and working capital allocation.
– Regulatory Compliance Management: Accounting teams utilize automated platforms to ensure compliance with dynamic tax codes and international accounting standards.

Core Implementation Recommendations
1. Deploy Automated Reconciliation Tools: Integrate continuous transaction processing modules into existing enterprise ERP architectures.
2. Establish Algorithmic Governance Controls: Implement strict internal testing protocols to ensure automated accounting rules comply with GAAP/IFRS standards.
3. Reskill Accounting Teams: Invest in training finance staff on data analytics, workflow automation, and predictive financial modeling.

Continue Reading

Accounting

Global ESG Reporting Standards and Double Materiality Compliance

Published

on

Corporate accounting departments face expanding reporting expectations as international sustainability disclosure standards achieve regulatory enforcement across major global jurisdictions. Chief Accounting Officers (CAOs) and corporate controllers are establishing rigorous internal accounting controls to treat Environmental, Social, and Governance (ESG) metrics with the same data precision, auditability, and governance as traditional financial statements.

Regulatory Harmonization Under Global Sustainability Frameworks
The implementation of standardized sustainability reporting frameworks—notably rules established by international sustainability accounting boards—has created unified expectations for public and large private enterprises. Corporations must report standardized metrics covering greenhouse gas emissions (Scope 1, 2, and material Scope 3), energy utilization, workforce demographics, and supply chain governance.

In Europe and other participating international jurisdictions, double materiality principles are mandatory. Under double materiality, organizations must report both how external sustainability risks impact corporate financial performance, and how internal corporate operations affect surrounding environmental and social structures.

Integrating Sustainability Metrics into Core ERP Systems
To provide auditable non-financial data, enterprise organizations are integrating specialized carbon accounting and ESG management platforms directly into core ERP systems. Automated data collectors capture energy utility invoices, logistics fuel consumption metrics, and vendor compliance records in real time.

Establishing automated, traceable data pipelines ensures that non-financial reporting is supported by clear audit trails. This structured approach allows external financial auditors to provide reasonable assurance on sustainability disclosures during annual corporate reporting cycles.

Financial Impacts and Capital Market Disclosure
Accurate ESG reporting directly influences corporate cost of capital and institutional credit ratings. Commercial lenders and institutional asset managers systematically incorporate sustainability metrics into risk pricing models. Companies that demonstrate transparent, verifiable progress in operational energy efficiency and climate risk mitigation benefit from expanded access to green bond markets and lower debt pricing.

Action Steps for Accounting Leadership
1. Implement Double Materiality Frameworks: Conduct comprehensive assessments to identify material financial and operational sustainability metrics.
2. Build Auditable Non-Financial Data Pipelines: Automate ESG data collection within core accounting software to ensure data integrity.
3. Align Sustainability with Annual Financial Filings: Prepare non-financial disclosures concurrently with financial statements to satisfy regulatory audit expectations.

Continue Reading

Trending